Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T cell therapies (CAR-T), announces today that the Company will publish its financial and operational results for the year 2022 on the evening of Thursday, March 23, 2023.
Following the Press Release, the Celyad Oncology management team will hold a conference call on Friday, March 24, 2023 at 1:00 p.m. CET / 8:00 a.m. ET, to discuss the 2022 financial results and to provide an update on recent changes as well as future important milestones for the Company.
Participants can access the conference call by dialing one of the following numbers: +1-877-407-9716 or +1-201-493-6779 (US, International), +32 (0) 800-73-904 (Belgium fixed) or +32 (0) 800-73-566 (Belgium mobile).
Attendees can also access the conference online for instant phone access to the event. The audio recording of the conference will be available after the event on the “Events” page of the Celyad Oncology website.